Avidity Partners Management »

Immuneering Corp - Class A shares owned by Avidity Partners Management

Quarter-by-quarter ownership of Immuneering Corp - Class A (IMRX) shares owned by Avidity Partners Management from 13F filings

Historical chart of Avidity Partners Management investment in Immuneering Corp - Class A

Tip: Access up to 7 years of quarterly data

All positions including Immuneering Corp - Class A held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immuneering Corp - Class A by Avidity Partners Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $636k 91k 7.00

More positions owned by Avidity Partners Management

Dianthus Therapeutics (DNTH)
Cg Oncology (CGON)
Medtronic SHS (MDT)
Boston Scientific Corporation (BSX)
Oruka Therapeutics (ORKA)
Bristol Myers Squibb (BMY)
Natera (NTRA)
Danaher Corporation (DHR)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Perspective Therapeutics Com New (CATX)
Jade Biosciences Com New (JBIO)
Pfizer (PFE)
Thermo Fisher Scientific (TMO)
Context Therapeutics (CNTX)
Genmab A/s Sponsored Ads (GMAB)

View all positions for Avidity Partners Management

Top funds holding Immuneering Corp - Class A

FMR
Sanofi
Vanguard Group
ExodusPoint Capital Management
Logos Global Management
Citadel Advisors
BlackRock
Blue Owl Capital Holdings
Geode Capital Management
Monashee Investment Management
Burkehill Global Management
Iridian Asset Management
Southport Management
Marshall Wace
Diametric Capital

View all funds holding Immuneering Corp - Class A